Skip to content

CLARITI (TM) 1-Day Multifocal Contact Lenses Performance and Acceptance Evaluation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02147093
Enrollment
41
Registered
2014-05-26
Start date
2014-05-01
Completion date
2014-08-01
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia Correction

Brief summary

A comparative evaluation of a newly marketed multifocal contact lens with a single vision contact lens when used with near vision spectacles. The evaluation was to quantify the difference between the two test corrections.

Interventions

DEVICETest (multi-focal)

contact lens was to be worn a daily wear.

DEVICEControl (Sphere)

contact lens was to be worn a daily wear with spectacles

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age 45 years or more 2. Spectacle or soft contact lens wearer 3. Refraction: best sphere (corrected for back vertex distance) -6.00 Diopters (D) to +4.00 D; Astigmatism - 0.00 D to -0.75 D; Near addition for 40 cm; Medium Add: +1.50 D to +2.00 D; High Add: +2.25 D to +2.50 D 4. Best spectacle corrected visual acuity of 6/9 or better in each eye 5. Willingness to adhere to the instructions set forth in the clinical protocol 6. Signature of the subject Informed Consent form after review of Information to Participant document.

Exclusion criteria

1. Systemic or ocular allergies which might interfere with contact lens wear 2. Systemic disease which might interfere with contact lens wear 3. Ocular disease which might interfere with contact lens wear (e.g. hypothesia, insufficient lacrimal secretion) 4. Use of medication which might interfere with contact lens wear 5. Active ocular infection 6. Use of ocular medication 7. Significant ocular anomaly 8. Presence of two or more corneal scars in either eye 9. Monovision contact lens wearers 10. Pregnancy or lactation 11. Any medical condition that might be prejudicial to the study 12. Participants non-able to give consent or from a vulnerable group 13. Infectious disease (for example, hepatitis, tuberculosis, etc.) or a contagious immunosuppressive disease (such as HIV, AIDS, etc.) 14. Employees or family member of the investigational clinic (e.g. investigator, coordinator, technician)

Design outcomes

Primary

MeasureTime frameDescription
Distance LogMAR Visual Acuity7 days post wearDistance time controlled LogMAR (Logarithm of the Minimum Angle of Resolution) Visual Acuity was carried out binocularly, at 4m (meter) under 250 cd/m\^2 and 2.5 cd/m\^2 (candela per square meter) luminance. The test was presented under the two conditions; High luminance (250 cd/m\^2) High Contrast (90%) & Low Contrast (10%) and Low Luminance (2.5 cd/m\^2) High Contrast (90%)
Near LogMAR Visual Acuity7 days post wearNear time controlled LogMAR Visual Acuity was carried out binocularly, at 4cm under 250 cd/m\^2 and 50 cd/m\^2 luminance. The test was presented on under the two conditions; High Luminance (250cd/m\^2) High Contrast (90%) & Low Contrast (10%) and Low Luminance (50cd/m\^2) High Contrast (90%)

Countries

United Kingdom

Participant flow

Recruitment details

A total of 41 subjects were enrolled in this study. Of the enrolled subjects 1 did not meet the eligibility criteria and 40 subjects were dispensed a study lens. Of the dispensed subjects, 3 were discontinued and 37 subjects completed the study.

Participants by arm

ArmCount
Control (Filcon II 3-sphere) /Test (Filcon II 3-multi-focal)
All subjects that were randomized to sequence and were dispensed a study lens.
20
Test (Filcon II 3-multi-focal) / Control (Filcon II 3-spher)
All subjects that were randomized to sequence and were dispensed a study lens.
20
Total40

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1Lost to Follow-up01
Period 2Protocol Violation20

Baseline characteristics

CharacteristicControl (Filcon II 3-sphere) /Test (Filcon II 3-multi-focal)Test (Filcon II 3-multi-focal) / Control (Filcon II 3-spher)Total
Age, Continuous56.20 years
STANDARD_DEVIATION 7.682
58.00 years
STANDARD_DEVIATION 9.067
56.78 years
STANDARD_DEVIATION 8.49
Region of Enrollment
United Kingdom
20 participants20 participants40 participants
Sex: Female, Male
Female
14 Participants12 Participants26 Participants
Sex: Female, Male
Male
6 Participants8 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

Primary

Distance LogMAR Visual Acuity

Distance time controlled LogMAR (Logarithm of the Minimum Angle of Resolution) Visual Acuity was carried out binocularly, at 4m (meter) under 250 cd/m\^2 and 2.5 cd/m\^2 (candela per square meter) luminance. The test was presented under the two conditions; High luminance (250 cd/m\^2) High Contrast (90%) & Low Contrast (10%) and Low Luminance (2.5 cd/m\^2) High Contrast (90%)

Time frame: 7 days post wear

Population: All subjects that completed all study visits without a major protocol deviation.

ArmMeasureGroupValue (MEAN)Dispersion
Control (Filcon II 3-sphere)Distance LogMAR Visual AcuityHigh Contrast-Distance-Standard High Luminance-0.466 LogMARStandard Deviation 0.9995
Control (Filcon II 3-sphere)Distance LogMAR Visual AcuityLow Contrast-Distance-Standard High Luminance-2.842 LogMARStandard Deviation 1.685
Control (Filcon II 3-sphere)Distance LogMAR Visual AcuityHigh Contrast-Distance-Standard Low Luminance-2.834 LogMARStandard Deviation 1.0042
Test (Filcon II 3-multi-focal)Distance LogMAR Visual AcuityHigh Contrast-Distance-Standard High Luminance-0.972 LogMARStandard Deviation 1.0104
Test (Filcon II 3-multi-focal)Distance LogMAR Visual AcuityLow Contrast-Distance-Standard High Luminance-3.768 LogMARStandard Deviation 1.8023
Test (Filcon II 3-multi-focal)Distance LogMAR Visual AcuityHigh Contrast-Distance-Standard Low Luminance-3.700 LogMARStandard Deviation 0.8939
Primary

Near LogMAR Visual Acuity

Near time controlled LogMAR Visual Acuity was carried out binocularly, at 4cm under 250 cd/m\^2 and 50 cd/m\^2 luminance. The test was presented on under the two conditions; High Luminance (250cd/m\^2) High Contrast (90%) & Low Contrast (10%) and Low Luminance (50cd/m\^2) High Contrast (90%)

Time frame: 7 days post wear

Population: All subjects that completed all study visits without a major protocol deviation.

ArmMeasureGroupValue (MEAN)Dispersion
Control (Filcon II 3-sphere)Near LogMAR Visual AcuityHigh Contrast-Near-Standard High Luminance-1.455 LogMARStandard Deviation 0.6309
Control (Filcon II 3-sphere)Near LogMAR Visual AcuityLow Contrast-Near-Standard High Luminance-2.151 LogMARStandard Deviation 1.0221
Control (Filcon II 3-sphere)Near LogMAR Visual AcuityHigh Contrast-Near-Standard Low Luminance-1.878 LogMARStandard Deviation 1.0546
Test (Filcon II 3-multi-focal)Near LogMAR Visual AcuityHigh Contrast-Near-Standard High Luminance-2.545 LogMARStandard Deviation 1.124
Test (Filcon II 3-multi-focal)Near LogMAR Visual AcuityLow Contrast-Near-Standard High Luminance-3.820 LogMARStandard Deviation 1.4124
Test (Filcon II 3-multi-focal)Near LogMAR Visual AcuityHigh Contrast-Near-Standard Low Luminance-3.441 LogMARStandard Deviation 1.3941

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026